aTyr Pharma Inc.

Case Overview
60 Days Left to Seek Lead Plaintiff
Lead Plaintiff Deadline: | Lead Plaintiff Deadline: 12/08/2025 |
Status: | Status: Investigating |
Company Name: | Company Name: aTyr Pharma Inc. |
Court: | Court: Southern District of California |
Case Number: | Case Number: 3:25cv02681 |
Class Period: | Class Period: 01/16/2025 - 09/12/2025 |
Ticker: | Ticker: ATYR |
Related Attorneys: | Lead Attorneys: Thomas W. Elrod |
Related Practices: | Related Practices: Securities |
The lawsuit alleges that aTyr made false and/or misleading statments to investors concerning aTyr’s Phase 3, randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of intravenous Efzofitimod in patients with pulmonary sarcoidosis (EFZO-FIT). Defendants’ statements included, among other things, aTyr’s top executives’ confidence in the forced taper approach of the Company’s study design. Defendants provided these overwhelmingly positive statements to investors while, at the same time, disseminating false and misleading statements and/or concealing material adverse facts concerning the efficacy of Efzofitimod, particularly, the drug’s capability to allow a patient to completely taper their steroid usage. This caused Plaintiff and other shareholders to purchase aTyr’s securities at artificially inflated prices.